HomeCompareDACHF vs ABBV

DACHF vs ABBV: Dividend Comparison 2026

DACHF yields 4.16% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 DACHF wins by $11.60M in total portfolio value· pulled ahead in Year 2
10 years
DACHF
DACHF
● Live price
4.16%
Share price
$8.44
Annual div
$0.35
5Y div CAGR
71.7%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$11.70M
Annual income
$9,653,176.75
Full DACHF calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — DACHF vs ABBV

📍 DACHF pulled ahead of the other in Year 2

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodDACHFABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, DACHF + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
DACHF pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

DACHF
Annual income on $10K today (after 15% tax)
$353.96/yr
After 10yr DRIP, annual income (after tax)
$8,205,200.24/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, DACHF beats the other by $8,184,144.23/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of DACHF + ABBV for your $10,000?

DACHF: 50%ABBV: 50%
100% ABBV50/50100% DACHF
Portfolio after 10yr
$5.90M
Annual income
$4,838,974.25/yr
Blended yield
81.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

DACHF
No analyst data
Altman Z
2.0
Piotroski
5/9
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

DACHF buys
0
ABBV buys
0
No recent congressional trades found for DACHF or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricDACHFABBV
Forward yield4.16%3.06%
Annual dividend / share$0.35$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR71.7%40.6%
Portfolio after 10y$11.70M$102.3K
Annual income after 10y$9,653,176.75$24,771.77
Total dividends collected$11.50M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: DACHF vs ABBV ($10,000, DRIP)

YearDACHF PortfolioDACHF Income/yrABBV PortfolioABBV Income/yrGap
1$11,415$715.00$11,550$430.00$135.00ABBV
2← crossover$13,524$1,309.68$13,472$627.96+$52.00DACHF
3$16,960$2,489.85$15,906$926.08+$1.1KDACHF
4$23,158$5,010.66$19,071$1,382.55+$4.1KDACHF
5$35,758$10,978.76$23,302$2,095.81+$12.5KDACHF
6$65,464$27,202.50$29,150$3,237.93+$36.3KDACHF
7$149,960$79,913.86$37,536$5,121.41+$112.4KDACHF
8$454,211$293,754.32$50,079$8,338.38+$404.1KDACHF
9$1,913,762$1,427,755.53$69,753$14,065.80+$1.84MDACHF
10$11,700,902$9,653,176.75$102,337$24,771.77+$11.60MDACHF

DACHF vs ABBV: Complete Analysis 2026

DACHFStock

Daicel Corporation engages in the medical/healthcare, smart, safety, materials, engineering plastics, and other businesses in Japan, China, and internationally. The company offers 1,3-Butylene glycol and polyglycerin for cosmetics; chiral and achiral columns/stationary phases, analytical tools, analytical/purification/synthesis/formulation services, chiral and bio reagents, analytical standards, and DNA and RNA-based probes; triacetylcellulose, high performance film, solvent for electronic materials, polymer for resist, semiconductor process cleaning agent, optical parts and lens unit, silver nanoparticle ink, and organic semiconductor devices; and inflators, pyro-fuse, and safety device for non-mobility products; and acetic acid and derivatives, cellulose acetate, acetate tow, cycloaliphatic epoxies, caprolactone, ketene derivatives, and alkylamines. It also provides ceramide derived from konjac root, equol derived from soybeans, ß-cryptoxanthin derived from citrus unshiu, and lactobionic acid derived from milk; DiSPERZiSTA, a dispersible filler for dietary supplement tablet; and MOiSTCARM, a make granules easy to swallow. In addition, the company offers engineering plastics and plastic compound products, high performance polymer, functional sheets, formed trays, and packaging films; water treatment systems and diffusers, such as UF membrane modules, ultra-fine bubble membrane diffusers, and E mizu showers. Its products are used in transportation, electronics, medical care, personal care, everyday life, and environment and energy applications. The company was formerly known as Daicel Chemical Industries, Ltd. and changed its name to Daicel Corporation in October 2011. Daicel Corporation was incorporated in 1919 and headquartered in Osaka, Japan.

Full DACHF Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this DACHF vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

DACHF vs SCHDDACHF vs JEPIDACHF vs ODACHF vs KODACHF vs MAINDACHF vs JNJDACHF vs MRKDACHF vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.